Invenomic Capital Management LP Takes $1.45 Million Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Invenomic Capital Management LP acquired a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 746,415 shares of the company’s stock, valued at approximately $1,448,000. Invenomic Capital Management LP owned about 0.30% of Lyell Immunopharma at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of LYEL. WuXi AppTec Co. Ltd. acquired a new stake in Lyell Immunopharma during the 4th quarter worth approximately $15,871,000. China Universal Asset Management Co. Ltd. increased its position in Lyell Immunopharma by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock worth $57,000 after purchasing an additional 22,701 shares in the last quarter. Public Employees Retirement System of Ohio increased its position in Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock worth $40,000 after purchasing an additional 14,229 shares in the last quarter. SG Americas Securities LLC increased its position in Lyell Immunopharma by 81.9% during the 4th quarter. SG Americas Securities LLC now owns 99,221 shares of the company’s stock worth $192,000 after purchasing an additional 44,686 shares in the last quarter. Finally, Profund Advisors LLC increased its position in Lyell Immunopharma by 20.0% during the 3rd quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock worth $108,000 after purchasing an additional 12,225 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Lyell Immunopharma in a report on Tuesday, May 7th.

Lyell Immunopharma Stock Performance

NASDAQ LYEL opened at $2.36 on Tuesday. Lyell Immunopharma, Inc. has a fifty-two week low of $1.32 and a fifty-two week high of $3.97. The business has a 50 day moving average price of $2.48 and a two-hundred day moving average price of $2.22.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Monday, May 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Lyell Immunopharma had a negative net margin of 335,794.09% and a negative return on equity of 33.92%. As a group, sell-side analysts forecast that Lyell Immunopharma, Inc. will post -0.85 EPS for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.